Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey

作者
Katarzyna Bazydło‐Guzenda,Paweł Buda,Mateusz Mach,Jerzy Pieczykolan,Izabela Kozłowska,Michal Janiszewski,Ewa Drzazga,Jakub Dominowski,Hubert Ziółkowski,Maciej Wieczorek,Shayne C. Gad
出处
期刊:PLOS ONE [Public Library of Science]
卷期号:16 (9): e0257477-e0257477 被引量:6
标识
DOI:10.1371/journal.pone.0257477
摘要

GPR40 (FFAR1) is a promising target for the managing type 2 diabetes (T2D). The most advanced GPR40 agonist TAK-875 exhibited satisfactory glucose-lowering effects in phase II and III studies. However, the phase III studies of TAK-875 revealed drug-induced liver injury (DILI). It is unknown whether DILI is a consequence of a specific GPR40 agonist or is an inherent feature of all GPR40 agonists. CPL207280 is a novel GPR40 agonist that improves diabetes in Zucker Diabetic Fatty (ZDF) rats, Goto Kakizaki (GK) rats and db/db mice. In this report, the DILI-related toxicity of CPL207280 was compared directly with that of TAK-875. In vitro studies evaluating hepatic biliary transporter inhibition, mitochondrial function, and metabolic profiling were performed in hepatocytes from different species. The long term toxicity of CPL207280 was studied in vivo in rats and monkeys. Activity of CPL207280 was one order of magnitude lesser than that of TAK-875 for the inhibition of bile acid transporters. CPL207280 had a negligible effect on the hepatic mitochondria. In contrast to TAK-875, which was metabolized through toxic glucuronidation, CPL207280 was metabolized mainly through oxidation. No deleterious hepatic effects were observed in chronically treated healthy and diabetic animals. The study presents promising data on the feasibility of creating a liver-safe GPR40 agonist. Additionally, it can be concluded that DILI is not a hallmark of GPR40 agonists; it is linked to the intrinsic properties of an individual agonist.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
逃跑计划发布了新的文献求助10
刚刚
jin完成签到,获得积分10
2秒前
Hello的应助被zoe采纳,获得10
2秒前
青光完成签到,获得积分10
2秒前
七听的应助被黄毛虎采纳,获得200
2秒前
观妙散人完成签到,获得积分10
3秒前
ygchyh发布了新的文献求助30
4秒前
JiaYouguo发布了新的文献求助20
4秒前
4秒前
健康的人生完成签到,获得积分10
4秒前
NexusExplorer的应助被糖糖采纳,获得10
4秒前
4秒前
4秒前
lindollar发布了新的文献求助30
5秒前
Augenstern完成签到,获得积分10
6秒前
丘比特的应助被吱吱采纳,获得10
6秒前
冰糖葫芦娃完成签到,获得积分10
6秒前
7秒前
7秒前
qfgp完成签到 ,获得积分10
7秒前
8秒前
大个的应助被嘿嘿采纳,获得10
8秒前
8秒前
Nole的应助被向日葵采纳,获得10
9秒前
qikuu发布了新的文献求助100
9秒前
罗实发布了新的文献求助10
10秒前
丘比特的应助被zzz采纳,获得10
10秒前
852的应助被睡梦无尘采纳,获得10
10秒前
ZenithL发布了新的文献求助10
10秒前
多边形发布了新的文献求助10
11秒前
温良完成签到 ,获得积分10
11秒前
Sxq完成签到,获得积分10
11秒前
结实初兰完成签到 ,获得积分20
11秒前
tjl发布了新的文献求助10
12秒前
糖醋蛋白质完成签到,获得积分10
12秒前
打打的应助被陶炳君采纳,获得10
12秒前
13秒前
13秒前
kuzfxyy发布了新的文献求助10
13秒前
美丽依波完成签到 ,获得积分10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187226
求助须知:如何正确求助?哪些是违规求助? 9575395
关于积分的说明 21841040
捐赠科研通 7784958
什么是DOI,文献DOI怎么找? 3434935
关于科研通互助平台的介绍 2559355
邀请新用户注册赠送积分活动 2481808